Journal of Clinical Oncology, Vol 10, 599-605, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

DC Allred, GM Clark, AK Tandon, R Molina, DC Tormey, CK Osborne, KW Gilchrist, EG Mansour, M Abeloff and L Eudey
Department of Pathology, University of Texas Health Science Center, San Antonio 78284-7884.

PURPOSE: Amplification and/or overexpression of the HER-2/neu oncogene have been shown to correlate with poor clinical outcome in patients with axillary node-positive breast cancer. In contrast, the prognostic significance of HER-2/neu in node-negative disease is controversial. This study was undertaken to evaluate further the relationship between HER-2/neu and clinical outcome in node-negative disease. PATIENTS AND METHODS: Overexpression of HER-2/neu was evaluated by permanent-section immunohistochemistry in tumors from 613 patients with long-term clinical follow-up enrolled in the Intergroup Study 0011. Patients were stratified into low-risk (n = 307) and high-risk (n = 306) groups on the basis of tumor size and estrogen-receptor (ER) status. Low-risk patients were defined as having small (less than 3 cm), ER-positive tumors and were observed without additional treatment after initial surgery. High-risk patients had either ER-negative or large (greater than or equal to 3 cm), ER-positive tumors and were randomized to be observed (n = 146) or to receive adjuvant chemotherapy (n = 160) after surgery. RESULTS: The rate of HER-2/neu overexpression was 14.3% in all tumors combined and was higher in invasive carcinomas with (21.5%) than without (11.2%) a significant noninvasive or in situ histologic component (P less than .0001). There was no relationship between overexpression and clinical outcome in the natural history setting of combined low-risk and high-risk patients not receiving adjuvant therapy (n = 453). Based on the reasoning that the influence of HER-2/neu may have been obscured by high-risk features and/or the presence of noninvasive carcinoma, we also analyzed the subset of patients with low- risk lesions not containing a significant in situ component (n = 179). Patients of this group with HER-2/neu-positive tumors showed only 40% disease-free survival (DFS) at 5 years, compared with over 80% in patients with HER-2/neu-negative tumors (P less than .0001). A similar inverse correlation was observed between overexpression and overall survival in the same group of patients (P = .0001). In a separate analysis involving patients receiving adjuvant chemotherapy, those with HER-2/neu-negative tumors showed significantly improved DFS in response to therapy compared with patients with HER-2/neu-positive tumors. CONCLUSION: Overexpression of HER-2/neu is associated with poor clinical outcome in a subset of node-negative patients with small, ER- positive, predominantly invasive tumors and may play a role in resistance to adjuvant chemotherapy.

This article has been cited by other articles:

				S. Chia, B. Norris, C. Speers, M. Cheang, B. Gilks, A. M. Gown, D. Huntsman, I. A. Olivotto, T. O. Nielsen, and K. Gelmon Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers J. Clin. Oncol., December 10, 2008; 26(35): 5697 - 5704. [Abstract] [Full Text] [PDF]

				L. Pusztai Current Status of Prognostic Profiling in Breast Cancer Oncologist, April 1, 2008; 13(4): 350 - 360. [Abstract] [Full Text] [PDF]

				L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF]

				S.-S. Ko, Y.-S. Na, C.-S. Yoon, J.-Y. Park, H.-S. Kim, M.-H. Hur, H.-K. Lee, Y.-K. Chun, S.-S. Kang, B.-W. Park, et al. The Significance of c-erbB-2 Overexpression and p53 Expression in Patients With Axillary Lymph Node--Negative Breast Cancer: A Tissue Microarray Study International Journal of Surgical Pathology, April 1, 2007; 15(2): 98 - 109. [Abstract] [PDF]

				A. C. Wolff, M. E. H. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, M. Dowsett, P. L. Fitzgibbons, W. M. Hanna, A. Langer, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer J. Clin. Oncol., January 1, 2007; 25(1): 118 - 145. [Abstract] [Full Text] [PDF]

				D. M. Nguyen, K. Sam, A. Tsimelzon, X. Li, H. Wong, S. Mohsin, G. M. Clark, S. G. Hilsenbeck, R. M. Elledge, D. C. Allred, et al. Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype Clin. Cancer Res., September 1, 2006; 12(17): 5047 - 5054. [Abstract] [Full Text] [PDF]

				K. I. Pritchard, L. E. Shepherd, F. P. O'Malley, I. L. Andrulis, D. Tu, V. H. Bramwell, M. N. Levine, and the National Cancer Institute of Canada Clinical T HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy N. Engl. J. Med., May 18, 2006; 354(20): 2103 - 2111. [Abstract] [Full Text] [PDF]

				S. K. Mohsin, H. L. Weiss, M. C. Gutierrez, G. C. Chamness, R. Schiff, M. P. DiGiovanna, C.-X. Wang, S. G. Hilsenbeck, C. K. Osborne, D. C. Allred, et al. Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers J. Clin. Oncol., April 10, 2005; 23(11): 2460 - 2468. [Abstract] [Full Text] [PDF]

				M. Cianfrocca and L. J. Goldstein Prognostic and Predictive Factors in Early-Stage Breast Cancer Oncologist, November 1, 2004; 9(6): 606 - 616. [Abstract] [Full Text] [PDF]

				G. E. Konecny, C. Thomssen, H. J. Luck, M. Untch, H.-J. Wang, W. Kuhn, H. Eidtmann, A. d. Bois, S. Olbricht, D. Steinfeld, et al. HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1141 - 1151. [Abstract] [Full Text] [PDF]

				J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398. [Abstract] [Full Text] [PDF]

				J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy Oncologist, August 1, 2003; 8(4): 307 - 325. [Abstract] [Full Text] [PDF]

				R. Malayeri Can Endocrine Treatment for Hormone-Positive Premenopausal Women With Early Breast Cancer Replace Adjuvant Chemotherapy? J. Clin. Oncol., June 15, 2003; 21(12): 2444 - 2445. [Full Text] [PDF]

				N. K. Dakappagari, J. Pyles, R. Parihar, W. E. Carson, D. C. Young, and P. T. P. Kaumaya A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses J. Immunol., April 15, 2003; 170(8): 4242 - 4253. [Abstract] [Full Text] [PDF]

				I. Zemzoum, R. E. Kates, J. S. Ross, P. Dettmar, M. Dutta, C. Henrichs, S. Yurdseven, H. Hofler, M. Kiechle, M. Schmitt, et al. Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer J. Clin. Oncol., March 15, 2003; 21(6): 1022 - 1028. [Abstract] [Full Text] [PDF]

				A. Moliterni, S. Menard, P. Valagussa, E. Biganzoli, P. Boracchi, A. Balsari, P. Casalini, G. Tomasic, E. Marubini, S. Pilotti, et al. HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer J. Clin. Oncol., February 1, 2003; 21(3): 458 - 462. [Abstract] [Full Text] [PDF]

				L. G. Estevez, J. M. Cuevas, A. Anton, J. Florian, J. M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, and J. Fortes Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study Clin. Cancer Res., February 1, 2003; 9(2): 686 - 692. [Abstract] [Full Text] [PDF]

				M. P. DiGiovanna, P. Chu, T. L. Davison, C. L. Howe, D. Carter, E. B. Claus, and D. F. Stern Active Signaling by HER-2/neu in a Subpopulation of HER-2/neu-overexpressing Ductal Carcinoma in Situ: Clinicopathological Correlates Cancer Res., November 15, 2002; 62(22): 6667 - 6673. [Abstract] [Full Text] [PDF]

				G. K. Ellis, R. B. Livingston, J. R. Gralow, S. J. Green, and T. Thompson Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer J. Clin. Oncol., September 1, 2002; 20(17): 3637 - 3643. [Abstract] [Full Text] [PDF]

				M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens J. Clin. Oncol., July 15, 2002; 20(14): 3095 - 3105. [Abstract] [Full Text] [PDF]

				J. A. Zujewski "Build Quality in"--HER2 Testing in the Real World J Natl Cancer Inst, June 5, 2002; 94(11): 788 - 789. [Full Text] [PDF]

				A. M. Bajo, A. V. Schally, M. Krupa, F. Hebert, K. Groot, and K. Szepeshazi Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes PNAS, March 19, 2002; 99(6): 3836 - 3841. [Abstract] [Full Text] [PDF]

				P. Kauraniemi, M. Barlund, O. Monni, and A. Kallioniemi New Amplified and Highly Expressed Genes Discovered in the ERBB2 Amplicon in Breast Cancer by cDNA Microarrays Cancer Res., November 1, 2001; 61(22): 8235 - 8240. [Abstract] [Full Text] [PDF]

				L. N. Harris, L. Yang, V. Liotcheva, S. Pauli, J. D. Iglehart, O. M. Colvin, and T. S. Hsieh Induction of Topoisomerase II Activity after ErbB2 Activation Is Associated with a Differential Response to Breast Cancer Chemotherapy Clin. Cancer Res., June 1, 2001; 7(6): 1497 - 1504. [Abstract] [Full Text] [PDF]

				T. Petit, C. Borel, J.-P. Ghnassia, J.-F. Rodier, A. Escande, R. Mors, and P. Haegele Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the Neoadjuvant Setting Clin. Cancer Res., June 1, 2001; 7(6): 1577 - 1581. [Abstract] [Full Text] [PDF]

				H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]

				L. N. Harris, V. Liotcheva, G. Broadwater, M. J. Ramirez, P. Maimonis, S. Anderson, T. Everett, D. Harpole, M. B. Moore, D. A. Berry, et al. Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy J. Clin. Oncol., March 15, 2001; 19(6): 1698 - 1706. [Abstract] [Full Text] [PDF]

				R. C. Bast Jr, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr, J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 15, 2001; 19(6): 1865 - 1878. [Abstract] [Full Text] [PDF]

				S. Eppenberger-Castori, W. Kueng, C. Benz, R. Caduff, Z. Varga, F. Bannwart, D. Fink, H. Dieterich, M. Hohl, H. Muller, et al. Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay J. Clin. Oncol., February 1, 2001; 19(3): 645 - 656. [Abstract] [Full Text] [PDF]

				S. Menard, P. Valagussa, S. Pilotti, L. Gianni, E. Biganzoli, P. Boracchi, G. Tomasic, P. Casalini, E. Marubini, M. I. Colnaghi, et al. Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node-Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables J. Clin. Oncol., January 15, 2001; 19(2): 329 - 335. [Abstract] [Full Text] [PDF]

				M. Ferrero-Poüs, K. Hacène, C. Bouchet, V. Le Doussal, M. Tubiana-Hulin, and F. Spyratos Relationship between c-erbB-2 and Other Tumor Characteristics in Breast Cancer Prognosis Clin. Cancer Res., December 1, 2000; 6(12): 4745 - 4754. [Abstract] [Full Text]

				D. Amadori, O. Nanni, M. Marangolo, P. Pacini, A. Ravaioli, A. Rossi, A. Gambi, G. Catalano, D. Perroni, E. Scarpi, et al. Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study J. Clin. Oncol., September 17, 2000; 18(17): 3125 - 3134. [Abstract] [Full Text] [PDF]

				M. S. Orr, P. M. O'Connor, and K. W. Kohn Effects of c-erbB2 Overexpression on the Drug Sensitivities of Normal Human Mammary Epithelial Cells J Natl Cancer Inst, June 21, 2000; 92(12): 987 - 994. [Abstract] [Full Text] [PDF]

				R. Colomer, S. Montero, A. Lluch, B. Ojeda, A. Barnadas, A. Casado, B. Massutí, H. Cortés-Funes, and B. Lloveras Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2356 - 2362. [Abstract] [Full Text]

				J. D. Hainsworth, W. J. Lennington, and F. A. Greco Overexpression of Her-2 in Patients With Poorly Differentiated Carcinoma or Poorly Differentiated Adenocarcinoma of Unknown Primary Site J. Clin. Oncol., February 1, 2000; 18(3): 632 - 632. [Abstract] [Full Text] [PDF]

				J. Chang, T. J. Powles, D. C. Allred, S. E. Ashley, G. M. Clark, A. Makris, L. Assersohn, R. K. Gregory, C. K. Osborne, and M. Dowsett Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer J. Clin. Oncol., October 1, 1999; 17(10): 3058 - 3063. [Abstract] [Full Text] [PDF]

				T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer J. Clin. Oncol., July 1, 1999; 17(7): 1974 - 1974. [Abstract] [Full Text] [PDF]

				T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System J. Clin. Oncol., July 1, 1999; 17(7): 1983 - 1983. [Abstract] [Full Text] [PDF]

				H. S. Pandha, L.-A. Martin, A. Rigg, H. C. Hurst, G. W.H. Stamp, K. Sikora, and N. R. Lemoine Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial of erbB-2-Directed Suicide Gene Expression J. Clin. Oncol., July 1, 1999; 17(7): 2180 - 2180. [Abstract] [Full Text] [PDF]

				R. J. Pietras, J. C. Poen, D. Gallardo, P. N. Wongvipat, H. J. Lee, and D. J. Slamon Monoclonal Antibody to HER-2/neuReceptor Modulates Repair of Radiation-induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene Cancer Res., March 1, 1999; 59(6): 1347 - 1355. [Abstract] [Full Text] [PDF]

				L. Zhang, Y.-K. Lau, W. Xia, G. N. Hortobagyi, and M.-C. Hung Tyrosine Kinase Inhibitor Emodin Suppresses Growth of HER-2/neu-overexpressing Breast Cancer Cells in Athymic Mice and Sensitizes These Cells to the Inhibitory Effect of Paclitaxel Clin. Cancer Res., February 1, 1999; 5(2): 343 - 353. [Abstract] [Full Text] [PDF]

				J. S. Ross and J. A. Fletcher The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy Stem Cells, November 1, 1998; 16(6): 413 - 428. [Abstract] [Full Text]

				J. S. Ross and J. A. Fletcher The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy Oncologist, August 1, 1998; 3(4): 237 - 252. [Abstract] [Full Text]

				F. Revillion, L. Hornez, and J.-P. Peyrat Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR Clin. Chem., November 1, 1997; 43(11): 2114 - 2120. [Abstract] [Full Text] [PDF]

				T. L. Gramlich, C. Fritsch, C. Cohen, M. Samuel, D. Hunt, P. J. Dean, and T. Gansler Oncogene Expression and Amplification in Barrett Adenocarcinoma International Journal of Surgical Pathology, April 1, 1997; 4(4): 203 - 211. [Abstract] [PDF]

				H. B. Muss, A. D. Thor, D. A. Berry, T. Kute, E. T. Liu, F. Koerner, C. T. Cirrincione, D. R. Budman, W. C. Wood, M. Barcos, et al. c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer N. Engl. J. Med., May 5, 1994; 330(18): 1260 - 1266. [Abstract] [Full Text]